HC
ALXN

HHG & Company’s Alexion Pharmaceuticals ALXN Stock Holding History

HHG & Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,216
Closed -$225K – 207
2014
Q4 		$225K Buy
+1,216
New +$225K 0.05% 188

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HHG & Company's ALXN Position: Q1 2015 in Review

HHG & Company sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 1,216 shares — an estimated $225K sold.

HHG & Company first reported a position in ALXN in Q4 2014 and held it in 1 quarter. The position peaked at $225K in Q4 2014. 565 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • HHG & Company reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • HHG & Company sold 1,216 Alexion Pharmaceuticals shares in Q1 2015, an estimated $225K.
  • HHG & Company first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • HHG & Company's Alexion Pharmaceuticals position peaked at $225K in Q4 2014.
  • 565 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on HHG & Company's 13F filing for Q1 2015, filed 27 Apr 2015.